FRONTEO Inc. (Headquarters: Minato-ku, Tokyo, President: Masahiro Morimoto, hereinafter FRONTEO) and MOLCURE Inc. (Headquarters: Kawasaki City, Kanagawa Prefecture, Representative Director: Takashi Ogawa, hereinafter MOLCURE) are creating using AI. We have signed a basic agreement on a business alliance agreement to promote drug DX (digital transformation).

　MOLCURE has drug molecule design technology using AI, and provides a biotechnology platform for short-term biopharmacy search and a fully automatic drug discovery system that automates the experimental process performed in wet laboratories. It is a venture company.It is possible to design biopharmaceutical molecules that cannot be discovered by existing methods, and at the same time, research and development of AI products with the mission of improving the speed and efficiency of drug development and providing better biopharmaceutical molecules to pharmaceutical companies faster. In addition to conducting bio-experiments such as screening and NGS analysis in our own laboratory.In particular, we have strengths in molecular design of peptide / antibody drugs, and we are creating structures for drugs that could not be developed by existing methods, improving the design of existing molecules, and searching for candidate substances in a short time.

　On the other hand, in the life science AI business, FRONTEO has a paper search AI system "Amanogawa" that analyzes a huge amount of paper and literature information in a short time, and displays molecules and genes related to diseases in a pathway map and is related. We are developing and marketing various solutions that promote drug discovery DX, such as the drug discovery support AI system "Cascade Eye" that visualizes the overall picture.

　Through this alliance, using the AI ​​technologies of both companies, for example, FRONTEO will discover and select targets for new therapeutic agents and drug repositioning, MOLCURE will design molecules, and from candidate selection to confirmation of effectiveness and feasibility. It will be possible to significantly speed up and improve efficiency in drug discovery research, such as building a rapid AI drug discovery model.We also believe that it will contribute to the further strengthening of the drug discovery support business, such as research and development of AI software with higher versatility and practicality for medical and drug discovery sites.

　FRONTEO will continue to contribute to reducing the development period and cost of drug discovery research, improving the probability of success, responding to unmet medical needs, improving the quality of medical care, etc. through in-house research and development and collaboration with partner companies. ..

　The impact of this matter alone on FRONTEO's business results for the current fiscal year is minor, but we will promptly notify you if there are any matters to be disclosed.

■Amanogawaabout URL: https://lifescience.fronteo.com/aidiscovery/amanogawa/

"Amanogawa (trademark / patent pending)" is a paper search AI system equipped with FRONTEO's original AI engine "Concept Encoder (registered trademark: concept encoder, reading: concept encoder)".When a researcher inputs a sentence such as a word or hypothesis of interest, "Concept Encoder" instantly detects the article related to the input content from the large number of articles published in PubMed *.

Since the search results are plotted in a map according to the similarity between the articles, you can check the relevance at a glance, and drag the article information detected on the map to narrow down the search, which is a visual that has never been seen before. You can search for articles.In addition, you can sort the search results in order of relevance and list their abstracts, greatly streamlining your article search.This makes it possible to discover events and new drug targets from a perspective that is difficult for humans to notice.

* PubMed: A database that allows you to search for articles in the field of biomedical science.Created by the National Center for Biological Sciences in the National Library of Medicine.

■ About Cascade Eye　URL: https://lifescience.fronteo.com/aidiscovery/cascade-eye/
"Cascade Eye (trademark / patent pending)" is a drug discovery support AI system equipped with FRONTEO's original AI engine "Concept Encoder (registered trademark: concept encoder, reading: concept encoder)". We are learning the latest paper information published in PubMed, and when you enter a disease name, molecules and genes related to that disease are displayed in a pathway map, and the connections and overall picture of each are analyzed and visualized.Therefore, it is possible to greatly improve the efficiency of target search, and it is difficult to realize by human research such as discovering the possibility of diversion of existing drugs used in different diseases and identifying biomarkers that have not been found so far. Enables an innovative drug discovery approach.

■ About MOLCURE Co., Ltd.　URL: https://molcure.com/

MOLCURE Co., Ltd. is a bio-venture company with unique high-performance biopharmacy molecular design technology that makes full use of AI, evolutionary molecular engineering, next-generation sequencing, and experiment automation technology.We are contributing to the development of innovative biopharmacy by creating high-performance drugs that were difficult to develop with existing methods.

■FRONTEOabout　URL: https://www.fronteo.com/

FRONTEO uses the in-house developed AI engine "KIBIT" and "concept encoder" specializing in natural language processing to extract meaningful and important information from a huge amount of text data to support corporate business. A data analysis company. Since its establishment in August 2003, it has been expanding globally to Japan, the United States, South Korea, and Taiwan, with a focus on legal tech businesses such as "e-discovery (electronic discovery)" and "digital forensic investigation" that support international litigation of companies. Has been deployed.Based on the AI ​​technology cultivated in the legal tech business, we expanded the business field to the life science field, business intelligence field, and OSINT from 8, and created by using AI to "turn text data into knowledge". We contribute to solving various corporate issues such as drug support, dementia diagnosis support, financial, human resources, and sales support. Listed on TSE Mothers on June 2014, 2007. January 6 Obtained a first-class medical device manufacturing and sales license (permit number: 26B2021X1).The capital is 13 thousand yen (as of March 1, 10350).

* FRONTEO, KIBIT, and concept encoder are registered trademarks of FRONTEO in Japan.